According to LUX-Lung 3 and LUX-Lung 6 studies, afatinib had a significant better response rate and prolonged progression-free survival (PFS) as compared with pemetrexed plus cisplatin or gemcitabine plus cisplatin in patients with treatment-naïve advanced lung adenocarcinoma harboring activating EGFR mutations [6, 7]. This evidence concerns the gene EGFR and lung adenocarcinoma.